Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32,370 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjects.
Cao B, Huang L, Liu M, Lin H, Ma T, Zhao Y, Geng Y, Yang Y, Guo H, Li J. Cao B, et al. Among authors: huang l. Expert Opin Drug Metab Toxicol. 2023 Sep;19(9):653-664. doi: 10.1080/17425255.2023.2260738. Epub 2023 Oct 12. Expert Opin Drug Metab Toxicol. 2023. PMID: 37811634 Clinical Trial.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study.
Lin D, Xiao H, Yang K, Li J, Ye S, Liu Y, Jing S, Lin Y, Yang Y, Huang L, Yuan J, Li Z, Yang J, Gao H, Xie Y, Xu M, Yan L. Lin D, et al. Among authors: huang l. BMC Med. 2024 May 29;22(1):209. doi: 10.1186/s12916-024-03394-z. BMC Med. 2024. PMID: 38807146 Free PMC article. Clinical Trial.
SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor.
Ma T, Dong Y, Huang L, Yang Y, Geng Y, Fei F, Xie P, Zhao Y, Lin H, Yang Z, Jin Y, Ju X, Sun R, Li J. Ma T, et al. Among authors: huang l. Front Pharmacol. 2022 Oct 19;13:1027627. doi: 10.3389/fphar.2022.1027627. eCollection 2022. Front Pharmacol. 2022. PMID: 36339534 Free PMC article.
The first selective VAP-1 inhibitor in China, TT-01025-CL: safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending doses.
Yang Y, Yu L, Sheng Z, Lin H, Weng Z, Song W, Cao B, Zhao Y, Gao Y, Ni S, Wang H, Ma T, Huang L, Sun C, Li J. Yang Y, et al. Among authors: huang l. Front Pharmacol. 2024 Apr 29;15:1327008. doi: 10.3389/fphar.2024.1327008. eCollection 2024. Front Pharmacol. 2024. PMID: 38741586 Free PMC article.
32,370 results
You have reached the last available page of results. Please see the User Guide for more information.